LAUSR

TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated diseases [1,2]. TNF-α may promote progression of endothelial dysfunction and, thus, of accelerated atherosclerosis [3]. There are several TNF-α inhibitors available for clinical use. Infliximab (IFX) is a chimeric human/murine IgG1 monoclonal antibody (mAb) that can induce the production of human anti-IFX Abs [2]. Adalimumab (ADA) may also induce the appearance of anti-ADA Abs despite that it is a fully recombinant human IgG1 mAb [1,2].